C-9JRAQu Biologics
Site Specific Immunomodulators, innate immunity, immunotherapy
trainingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-9JRA
C-9JRAC-9JRASite Specific Immunomodulators, innate immunity, immunotherapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Current trial: https://www.qubiologics.com/clinical-trials/periop-06-study/
Hal Gunn, Qu Biologics, Canada, presents at the 11th Aging Research and Drug Discovery meeting: Living Longer and Healthier by Training Innate Immunity: Transforming Aging
Dominika Wilczok interviews Dr. Hal Gunn: the founder and CEO of QuBiologics, the tier 3 sponsor of ARDD! 🔴Hal Gunn, MD, founder and CEO of Qu Biologics, is a physician-entrepreneur who has focused his professional life to understanding how to support the body’s innate immune capacity to heal. Dr. Gunn co-founded InspireHealth, Canada’s foremost supportive cancer care centres, to support the health, healing and immune system function of people undergoing cancer treatment and their families. Under Dr. Gunn’s leadership, InspireHealth grew to become a leader in supportive oncology with three centres in Canada, funded by government. Dr. Gunn was awarded the $250,000 Dr. Roger’s Prize for vision, leadership, and integrity in the field of Integrative Medicine. Dr. Gunn founded Qu Biologics to develop his discovery of the Site Specific Immunomodulation (SSI) platform, designed to restore the full depth and breadth of immune function in a targeted diseased organ, and is Qu’s CEO and a membe
This study is designed to test whether QBKPN SSI can improve immune function in older adults, including how well it can protect against respiratory and other infections, whether it improves the body's response to COVID-19 vaccines, what effect it has on maintaining or improving quality of life, activity level and health status and whether it has an effect on glycemic control. QBKPN is a new medication in a class known as Site-Specific Immunomodulators (SSI). SSIs are designed to train and/or improve innate immune function to reduce the risk of infections, improve immune response to cancer, and slow the progression of chronic inflammatory diseases. It is believed that QBKPN SSI can work with the immune system to help protect against respiratory and other infections.
Qu Biologics has developed a transformative first-in-class immunotherapy platform, Site Specific Immunomodulators (SSIs), that arms our first line of defense against infectious and non-infectious threats.SSIs are uniquely positioned to be implemented at the time of first emergence of a novel viral strain to be used both prophylactically and therapeutically. Qu Biologics is seeking funding/collaboration/partnership to rapidly progress QBKPN and its transformational potential into Phase 2 (randomized controlled trial in COVID-19 high risk group). Additional Qu Biologic Testimonials Around Proposed Covid-19 Trial: Dr. Hal Gunn CEO (Qu Biologics Inc.) https://youtu.be/eprzdSV6pM0 Dr. Shirin Kalyan (PhD) Director of Scientific Innovation (Qu Biologics Inc.) https://youtu.be/NRT7JTYBx4k Dr Hal Gunn, CEO of Qu Biologics, Vancouver, BC, Canada, along with co-founder Rob Freeman were interviewed by Dahlia Kurtz of AM Radio 580 Ottawa, Canada, about the proposed COVID-19 clinical trial: ht
Qu Biologics has developed a transformative first-in-class immunotherapy platform, Site Specific Immunomodulators (SSIs), that arms our first line of defense against infectious and non-infectious threats. SSIs are uniquely positioned to be implemented at the time of first emergence of a novel viral strain to be used both prophylactically and therapeutically. Qu Biologics is seeking funding/collaboration/partnership to rapidly progress QBKPN and its transformational potential into Phase 2 (randomized controlled trial in COVID-19 high risk group). Additional Qu Biologics Testimonials Around Proposed Covid-19 Trial: Dr. Simon Sutcliffe (MD, FRCP, FRCR, FRCPC) Past President & CEO, BC Cancer Agency (British Columbia, Canada) https://youtu.be/bNoVZWfXxK0 Dr. Hal Gunn CEO (Qu Biologics Inc.) https://youtu.be/eprzdSV6pM0 Dr Hal Gunn, CEO of Qu Biologics, Vancouver, BC, Canada, along with co-founder Rob Freeman were interviewed by Dahlia Kurtz of AM Radio 580 Ottawa, Canada, about the pr
Dr Hal Gunn, CEO of Qu Biologics https://www.qubiologics.com Vancouver, BC, Canada, along with co-founder Rob Freeman were interviewed by Dahlia Kurtz of AM Radio 580 Ottawa https://omny.fm/shows/580-cfra/the-goods-this-canadian-biotech-company-believes-i Qu Biologics believes it has an effective preventable solution for COVID-19: https://www.qubiologics.com/what-we-do/ssis-for-emerging-infections/ & is asking the Canadian Federal Government for $18M CDN to start the clinical trial. PDF showing overview of medical treatment, showing research: https://files.constantcontact.com/b6b6f484301/758df801-36e8-431a-8398-e9f91a938750.pdf
Current trial (2018) for Crohn's http://www.qubiologics.com/clinical-trials/crohns-disease/ All participants get the medicine, not placebo. While it's not known if she's permanently "cured", she's been "Colitis free" and in remission, for 5 years now (as of Oct 2018) after taking Qu Biologics SSI treatment. She's also been off all conventional Colitis medicines & finished her SSI treatment over 4 years ago. This video was filmed July 2013, & she continues to be free of Colitis, now, in Oct 2018. While Bailey had colitis, it's related to Crohn's, where Qu Biologics has focussed much of their effort: Here is a recent 2018 CTV news clip showing SSI success for Crohn's: https://london.ctvnews.ca/video?clipId=1459291 https://www.therecord.com/news-story/8807158-local-crohn-s-patient-sees-vast-improvement-with-clinical-trial/ A 2015 Crohn's SSI article in the St Marys Journal Argus: https://www.flickr.com/photos/143782791@N05/30466393742/ A 2015 "The Londoner" Crohn's SSI article : http:
The QBECO-CD-02 trial in subjects with moderate to severe Crohn's disease (CD) is intended to build on past experience with QBECO SSI and further establish the safety and efficacy of QBECO SSI for the induction of clinical and/or endoscopic response and remission. The study will be conducted in three stages; a Lead-in, Main Induction and Main Maintenance .The first 20 patients will be enrolled in the Lead-in study, at approximately 5 study centers in Canada. Subsequent patients will be enrolled in the Main study, which aims to enroll 150 patients. The Lead-in component will be an open-label study to evaluate endoscopic healing endpoints. The Main Induction study will be randomized and placebo-controlled. Participants meeting response criteria following the Main Induction study will be eligible to continue into the Main Maintenance study, remaining on their initially randomized treatment. Participants not meeting response criteria will complete their follow-up and study involvement at the end of the Main Induction.
In this webinar, broadcast on April 5th 2018, Dr. Hal Gunn outlines specifics about Qu Biologics' latest clinical trial of QBECO SSI for remission in adults with moderate to severe Crohn's disease. He discusses the study site locations and participation details as well as answering questions posed by the online audience.
Dr. Hal Gunn presents information about Qu Biologics' latest clinical trial for patients with Crohn's disease. RESTORE is a phase 2 clinical study of QBECO for the induction of maintenance of clinical and endoscopic remission in people with Crohn's disease.
Learn about a new Crohn's disease investigational treatment called site specific immunomodulators or SSIs. Principal Investigator & Gastroenterologist, Dr. Brian Bressler, Qu Biologics' Founder Dr. Hal Gunn, and Chief Medical Officer Dr. Simon Sutcliffe answer questions from gastroenterologists about the Phase 1/2 clinical trial. Learn about the clinical trial, how SSIs may work to treat the underlying cause of Crohn's, SSI history, and what trial participants can expect.
Qu Biologics’ CEO, Dr. Hal Gunn talks about his presentation of data from QBECO-01, Qu Biologics’ completed 68-patient double-blind randomized placebo-controlled trial, at Digestive Disease Week (DDW) in Chicago, on May 7th 2017. Digestive Disease Week is the world’s foremost gastroenterology annual conference.
In this educational video, Qu Biologics CEO Dr. Hal Gunn talks about QBECO SSI, a new investigational treatment being tested in clinical trials for Crohn's disease and ulcerative colitis. Current IBD treatments are designed to suppress the adaptive immune response that exists in inflammatory bowel disease. QBECO SSI works to restore innate immune system function, thereby clearing the dysbiosis and chronic bacterial infection so there’s no longer a trigger for the overactive adaptive immune response.
Dr. Hal Gunn demonstrates to patients how to administer QBECO SSI, an investigational new treatment for Crohn's disease. Qu Biologics develops Site Specific Immunomodulators (SSIs), a novel class of immunotherapies that aim to 'reboot' the body's innate immune system.
Qu Biologics' CEO Dr. Hal Gunn talks about a defect or deficiency that may underlie Crohn's disease and ulcerative colitis and how investigational treatment QBECO SSI is designed to restore the body's innate immune function.
Qu Biologics' co-founder Dr. Hal Gunn has dedicated his career to researching and learning about the immune system as it relates to cancer and autoimmune disease. In this video, Dr. Gunn talks about what inspired him to study cancer and immune-related disease, what he discovered during clinical practice about the immune system and how those findings led to founding Vancouver-based biopharmaceutical company Qu Biologics.
Qu Biologics' CEO Dr. Hal Gunn talks about Site Specific Immunomodulators (SSIs), investigational new treatments for autoimmune disease and cancer. Dr. Gunn describes the "hygiene hypothesis" which theorizes that we may be living in too sterile a world and that acute infection helps to stimulate the body's immune system. He speaks about how the body's immune system may respond to acute infection. Further, Dr. Gunn talks about Qu Biologics' research of immune system dysfunction and how SSIs, which are derived from inactivated bacterial components, may stimulate an innate immune response to immune-related diseases, such as Crohn's disease.
Qu Biologics has developed a platform of immunotherapies called Site Specific Immunomodulators (SSIs). SSIs are derived from components of inactivated bacteria, designed to restore the body’s normal immune function to treat cancer and other immune-related diseases. In the context of cancer, Qu Biologics' SSIs are designed to restore immune function and activate the patient’s own immune cells to clear cancer cells.Qu Biologics’ CEO Dr. Hal Gunn how Site Specific Immunomodulators work in the context of cancer treatment.
The purpose of this dose-escalation study is to assess the safety and pharmacodynamics of single and multiple doses of QBKPN SSI, administered subcutaneously to healthy adult volunteers
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response and remission in subjects with moderate to severe ulcerative colitis
Dr Hal Gunn, CEO of Qu Biologics http://www.qubiologics.com, accepts the "Growth Stage Life Sciences Company of the Year" award on behalf of Qu Biologics at the 17th Annual LifeSciences BC Awards, Vancouver, BC, Canada. http://www.lifesciencesbc.ca. Dr Simon Sutcliffe, our CMO (Chief Medical Officer) at Qu Biologics Inc., also received the Dr Don Rix Award for Lifetime Achievement: https://www.youtube.com/watch?v=CzjBpdyADt4. Congrats to Hal, Simon, and everyone at & associated with Qu and the Qu Crohn's Trial http://www.qucrohnstrial.com.
The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following surgical section of Stage 1 NSCLC.
The purpose of this study is to evaluate the safety profile and to obtain an indication as to the therapeutic effect of QBECO induction treatment on clinical improvement in moderate to severe Crohn's Disease.
Qu Biologics to Present in Victoria, Kamloops, Calgary and Edmonton - QuIBD Current Trials No active IBD trials operating at this time Past Trials Crohn’s Disease Phase 2 – “part #1” Clinical Trial Experience in Crohn’s disease Clinical Trial Experience in Ulcerative Colitis Intro to SSIs How SSIs Work SSI Clinical History QBECO SSI Efficacy & Safety IBD Clinical Advisors Clinical Trial Doctors Resources Why Participate in a Clinical Trial Impact of IBD What is Crohn’s Disease? What is Ulcerative Colitis? Differences between Crohn’s Disease & Ulcerative … integrative cancer care. In 2009, Dr. Gunn was awarded the $250,000 Dr. Roger’s Prize for vision, leadership and integrity in the field of Integrative Medicine. About Jill Orsten Jill Orsten was diagnosed with Crohn’s disease in the third grade. Despite frequent flare-ups she became a competitive equestrian show jumper, a curator of contemporary art, an artificial intelligence researcher and now a Development Coordinator at Crohn’s and Colitis Canada. Jill will speak about ho
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology! Access Free Conference Whitepapers! Register for our Free Newsletter! … unding employee of Deep Genomics – a biotechnology company focused on the application of artificial intelligence in drug development. He played a central role in crafting and operationalizing the company’s strategy, helped build the executive team, and led a variety of functions including finance, legal, HR, and business development. During his tenure, the company formed its first Pharma partnerships and raised more than USD$200M through multiple rounds of financi
Ошибка Facebook Приложение Facebook недоступно в этом браузере Чтобы продолжить пользоваться Facebook, установите один из указанных ниже браузеров. Подробнее Русский + © Meta, 2026
You need to enable JavaScript to run this app. Loading...
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's disease
BIO International Convention | June 22-25 | San Diego | Qu Biologics Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreeme
Quinnipiac University Podcast Studio Skip to main content Academics Back to main menu Your Tools for Success At Quinnipiac, we provide the knowledge and resources you need to make a tangible impact on your chosen field. Through a combination of classroom theory and practical experience designed for you to succeed, you'll experience the life-changing opportunity of working and learning in the community and around the globe. Rankings and Distinctions Academics Find Your Program Explore Areas of Interest Undergraduate Programs Bachelor's Degree Completion Programs Accelerated Dual-Degre … kes Quinnipiac so special. See Quinnipiac for yourself Admissions Undergraduate Apply Transfer Military International Visit Chat with a Student Connect With Your Counselor Graduate Apply Opens in a new tab or window. Military Opens in a new tab or window. International Opens in a new tab or window. Visit Opens in a new tab or window. Contact Grad Admissions Opens in a new tab or window. School of Law Apply Opens in a new tab or window. Visit Opens in a new tab or window. Cons … in a new tab or window. School of Medicine Visit Opens in a new tab or window. Residency Match Opens in a new tab or window. Related Resources Admitted Students Academic Calendar Visit and Tours Maps and Directions Student Consumer Information Tuition & Aid Back to main menu Paying for QU Choosing to pursue a degree is an investment in your future. We're here to help you find the support and resources to understand your options and make a plan for success. Tuition & … ; Aid Undergraduate Costs and Budgets Net Price Calculator Explore Types of Aid Apply for Financial Aid Contact Financial Aid FAQs Graduate Costs and Budgets Opens in a new tab or window. Explore Types of Aid Opens in a new tab or window. Apply for Financial Aid Opens in a new tab or window. Contact Financial Aid Opens in a new tab or window. FAQs Opens in a new tab or window. School of Law Opens in a new tab or window. Costs and Budgets Opens in a new tab or window. Types of … udgets Opens in a new tab or window. Types of Aid Opens in a new tab or window. Apply for Financial Aid Opens in a new tab or window. School of Medicine Opens in a new tab or window. Costs and Budgets Opens in a new tab or window. Types of Aid Opens in a new tab or window. Apply for Financial Aid Opens in a new tab or window. Related Resources Br
Home | Quinnipiac University Skip to main content Academics Back to main menu Your Tools for Success At Quinnipiac, we provide the knowledge and resources you need to make a tangible impact on your chosen field. Through a combination of classroom theory and practical experience designed for you to succeed, you'll experience the life-changing opportunity of working and learning in the community and around the globe. Rankings and Distinctions Academics Find Your Program Explore Areas of Interest Undergraduate Programs Bachelor's Degree Completion Programs Accelerated Dual-Degree Progra … kes Quinnipiac so special. See Quinnipiac for yourself Admissions Undergraduate Apply Transfer Military International Visit Chat with a Student Connect With Your Counselor Graduate Apply Opens in a new tab or window. Military Opens in a new tab or window. International Opens in a new tab or window. Visit Opens in a new tab or window. Contact Grad Admissions Opens in a new tab or window. School of Law Apply Opens in a new tab or window. Visit Opens in a new tab or window. Cons … in a new tab or window. School of Medicine Visit Opens in a new tab or window. Residency Match Opens in a new tab or window. Related Resources Admitted Students Academic Calendar Visit and Tours Maps and Directions Student Consumer Information Tuition & Aid Back to main menu Paying for QU Choosing to pursue a degree is an investment in your future. We're here to help you find the support and resources to understand your options and make a plan for success. Tuition & … ; Aid Undergraduate Costs and Budgets Net Price Calculator Explore Types of Aid Apply for Financial Aid Contact Financial Aid FAQs Graduate Costs and Budgets Opens in a new tab or window. Explore Types of Aid Opens in a new tab or window. Apply for Financial Aid Opens in a new tab or window. Contact Financial Aid Opens in a new tab or window. FAQs Opens in a new tab or window. School of Law Opens in a new tab or window. Costs and Budgets Opens in a new tab or window. Types of … udgets Opens in a new tab or window. Types of Aid Opens in a new tab or window. Apply for Financial Aid Opens in a new tab or window. School of Medicine Opens in a new tab or window. Costs and Budgets Opens in a new tab or window. Types of Aid Opens in a new tab or window. Apply for Financial Aid Opens in a new tab or window. Related Resources Br
Qu Biologics Completes Enrolment of a Unique Study Testing --> Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News Leisure Goods News Media & Entertainment News Personal Care News Retail News Travel and Leisure News Energy News Alternative Energy News Oil Gas and Coal News Chemicals News Banks & Financial Services News Banking News Closed-End Investments News Finance and Credit Services News Investment Banking and Brokerage Services News Insurance News Real Estate & REITs News Healthca
Home - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Qu Biologics' Site Specific Immunomodulators (SSIs) are designed to restore normal immune function to treat and prevent cancer, chronic inflammatory diseases, and metabolic disease. Learn More Helping the Body Heal Itself Transformational Science Qu Biologics is pioneering the developmen
Julia G. Levy PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Julia G. Levy PhD Advisor at Protokinetix, Inc. Julia G. Levy PhD 's Executive Work History Current Advisor , Advisor Equilar on 12/11/2025 Protokinetix, Inc. Past To view Julia G. Levy PhD's complete executive work history, sign up now Education B.A. … onal Business, Pacific Canada Entrepreneur of the Year and the Future of Vision Award from the Foundation Fighting Blindness. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. In her honour, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the BC Bi … onal Business, Pacific Canada Entrepreneur of the Year and the Future of Vision Award from the Foundation Fighting Blindness. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. In her honour, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the BC Bi
Mike Leschuk, CA, CPA - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Mike Leschuk, CA, CPA A Chartered Accountant by training, Mr. Leschuk brings a breadth of experience working with public and private companies to his Board role at Qu. Mr. Leschuk is President of Leschuk-Weisz Developments, a real estate development company. He also serv
Marc Lambiotte MBChB; MMED; FCP(SA), CERT; FRCPC - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Marc Lambiotte MBChB; MMED; FCP(SA), CERT; FRCPC Dr. Lambiotte is an internal medicine physician who has worked in the United Kingdom, South Africa, and Canada. Dr. Lambiotte’s interests lie in improving efficiencies in medicine, improving and
Karn Manhas, JD Law, BSc - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Karn Manhas, JD Law, BSc Karn Manhas is a multi-faceted leader and biotech executive, whose diverse leadership background spans being the youngest Member of the Legislative Assembly elected in British Columbia, a sought-after thought leader on sustainability and innov
Boost Your Immunity: Join Dr. Hal Gunn... - Qu Biologics Inc. Facebook Вход Публикация Qu Biologics Inc. Qu Biologics Inc. 27 январь 2025 г. · Поделился/-ась с Доступно всем Boost Your Immunity: Join Dr. Hal Gunn for a Presentation on Strengthening Your Immune System - Tailored for People 65+ Date: January 30, 2025 Time: 2:00 PM Location: Rideau Residence RSVP: Call/ Text Lianne at 778-837-7031 Все реакции: 4 Поставить "Нравится" Комментировать
Board of Directors Archives - Qu Biologics Skip to main content Skip to primary sidebar Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Board of Directors September 26, 2023 Marc Lambiotte MBChB; MMED; FCP(SA), CERT; FRCPC Dr. Lambiotte is an internal medicine physician who has worked in the United Kingdom, South Africa, and Canada. Dr. Lambiotte’s […] Read More > Sept
Facebook Познакомьтесь с тем, что вам нравится . Войдите на Facebook Электронный адрес или номер мобильного телефона Пароль Войти Забыли пароль? Создать новый аккаунт Русский English (UK) Українська Suomi 中文(简体) Deutsch العربية Другие языки... Зарегистрироваться Вход Messenger Facebook Lite Видео Meta Pay Магазин Meta Meta Quest Ray-Ban Meta Meta AI Instagram Threads Политика конфиденциальности Центр конфиденциальности Информация Создать объявление Создать Страницу Разработчикам Вакансии Файлы cookie Рекламные предпочтения Условия использования Справка Загрузка контактов и лица, не являющиеся
Hal Gunn, MD - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Hal Gunn, MD CEO Hal Gunn, MD, founder and CEO of Qu Biologics, is a physician-entrepreneur who has dedicated his professional life to understanding how to optimally support the body’s innate immune capacity to heal. Dr. Gunn is recognized both nationally and internationally as a … er in the field of supportive oncology and was awarded the $250,000 Dr. Roger’s Prize for Advancing Health, Medicine, and Healing for vision, leadership, and integrity in the field of Integrative Medicine. Dr. Gunn co-founded InspireHealth, Canada’s foremost supportive cancer care centre, to support the health, healing, and immune system function of people undergoing cancer treatment and their families. Under Dr. Gunn’s leadership, InspireHealth grew to become a world leader
Vice President – Chemistry, Manufacturing, and Control Archives - Qu Biologics Skip to main content Skip to primary sidebar Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Vice President – Chemistry, Manufacturing, and Control April 10, 2025 Arjune Premsukh, BSc Arjune Premsukh, BSc, is Qu Biologics’ Vice President of Chemistry, Manufacturing, and Control
Management Team Archives - Qu Biologics Skip to main content Skip to primary sidebar Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Management Team April 10, 2025 Arjune Premsukh, BSc Arjune Premsukh, BSc, is Qu Biologics’ Vice President of Chemistry, Manufacturing, and Control. He has over 25 years of experience […] Read More > September 26, 2023 Shirin Kalyan, PhD D
Arjune Premsukh, BSc - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Arjune Premsukh, BSc Vice President – Chemistry, Manufacturing, and Control Arjune Premsukh, BSc, is Qu Biologics’ Vice President of Chemistry, Manufacturing, and Control. He has over 25 years of experience in biologics drug development, including expertise in R … pment through to process performance qualification batches for Biologic License Application. He has successfully managed drug substance, drug product manufacturing processes, and method transfers to commercial CMO. At Qu Biologics, he is responsible for all aspects of drug development and production to ensure quality and consistency. He also oversees all aspects of in-house process development, process optimization and process characterization, method development and qualific
Qu Biologics Granted Broad New Zealand Patent Involving Immunotherapies Derived From Viruses For Treating A Range Of Cancers - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioForest Qu Biologics Granted Broad New Zealand Patent Involving Immunotherapies Derived From Viruses For Treating A Range Of Cancers June 5, 2014 | 3 min read Twitter LinkedIn Facebook Email Print Vancouver, British Columbia- June 4, 2014 - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics’ Immunomodulator Improves Fatty Liver Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Qu Biologics’ Immunomodulator Improves Fatty Liver Disease January 6, 2025 | 5 min read Twitter LinkedIn Facebook Email Print BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics Completes $8M Financing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Rele … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Qu Biologics Completes $8M Financing December 9, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics Co-Founder’s Cancer Recovery Fuels Desire To Help Others - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Qu Biologics Co-Founder’s Cancer Recovery Fuels Desire To Help Others February 11, 2015 | 1 min read Twitter LinkedIn Facebook Email Print Promising experimental treatments for Crohn’s disease and lung cancer being developed by Qu Biologics Inc., a Canadian biotechnology company founded by former London Telecom mogul Ro … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics Closes Private Financing Of CDN$4 Million - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases A … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Qu Biologics Closes Private Financing Of CDN$4 Million April 13, 2016 | 2 min read Twitter LinkedIn Facebook Email Print Vancouver, British Columbia - April 12, 2016 - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's normal immune response, announ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics Release: Positive Feedback From FDA Reviewers In Response To Pre-IND Meeting Package - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Ge … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioForest Qu Biologics Release: Positive Feedback From FDA Reviewers In Response To Pre-IND Meeting Package August 15, 2017 | 3 min read Twitter LinkedIn Facebook Email Print VANCOUVER, British Columbia, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodul … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics’ Immunomodulator Clears Senescence - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Qu Biologics’ Immunomodulator Clears Senescence February 11, 2025 | 5 min read Twitter LinkedIn Facebook Email Print BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a no … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer June 6, 2024 | 4 min read Twitter LinkedIn Facebook Email Print Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel pl … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor December 16, 2024 | 5 min read Twitter LinkedIn Facebook Email Print BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Spec … search with NUS Medicine shows that SSIs may be the breakthrough for successful application of CAR T-cell therapy for solid cancers that the field has been searching for.” For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com . Media Contact: Hal Gunn, MD CEO, Qu Biologics Inc. Phone: 604.734.1450 Email: [email protected] About Qu Biologics Qu Biologics is a clinical stage biotechnology company developing Site Specific … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu Biologics Completes Enrolment of a Unique Study Testing a Novel Immunomodulator to Restore Immune Function in the Elderly - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Qu Biologics Completes Enrolment of a Unique Study Testing a Novel Immunomodulator to Restore Immune Function in the Elderly July 24, 2025 | 4 min read Twitter LinkedIn Facebook Email Print VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
QuIBD, Author at QuIBD - Page 3 of 3 Current Trials No active IBD trials operating at this time Past Trials Crohn’s Disease Phase 2 – “part #1” Clinical Trial Experience in Crohn’s disease Clinical Trial Experience in Ulcerative Colitis Intro to SSIs How SSIs Work SSI Clinical History QBECO SSI Efficacy & Safety IBD Clinical Advisors Clinical Trial Doctors Resources Why Participate in a Clinical Trial Impact of IBD What is Crohn’s Disease? What is Ulcerative Colitis? Differences between Crohn’s Disease & Ulcerative Colitis Frequently Asked Questions Glos
Team and Board - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Team and Board Management Team Hal Gunn, MD CEO Simon Sutcliffe, MD, FRCP, FRCPC, FRCR Chief Medical Officer – Oncology Ted Steiner, MD, FRCPC Chief Medical Officer – Infectious Diseases Shirin Kalyan, PhD Vice President - Scientific Innovation Arjune Premsukh, BSc Vice Preside
Robert E. Pelzer, LLB - Qu Biologics Skip to main content Skip to footer Qu Biologics Who We Are Mission and Values Team and Board What We Do Transformational Science SSI Platform SSI Pipeline Publications Current Clinical Trial PERIOP-06 Study News In the Press Investors Careers Contact Search Search this website Close Search Robert E. Pelzer, LLB Mr. Robert E. Pelzer is an accomplished pharmaceutical leader with significant international experience. He was most recently President of Novartis Corporation and served as its Head of Legal Affairs. In that capacity, Mr. Pelzer was responsible for
Fighting the cancellation of the basic income project, Ontario challenges federal carbon tax, Crohn's clinical trial in Hamilton & Festival of Friends kicks off at Gage Park | Hamilton Today with Scott Thompson Episodio en Amazon Music Inicio Inicio Podcasts Podcasts Biblioteca Cancelar Iniciar sesión Fighting the cancellation of the basic income project, Ontario challenges federal carbon tax, Crohn's clinical trial in Hamilton & Festival of Friends kicks off at Gage Park Hamilton Today with Scott Thompson 03-08-2018 • 55 minutos Advocates for the basic income project are looking
Fighting cancer and other diseases naturally with immune-stimulators; Qu Biologics clinical trial revives an old theory | Vancouver Sun Advertisement oop Story continues below This advertisement has not loaded yet, but your article continues below. Skip to Content Vancouver Sun merchandise celebrating local stories and the community you love. Shop now >> Vancouver Sun merchandise celebrating local stories and the community you love. Shop now >> Sections Search Search vancouversun.com Perform search Vancouver Sun Share Share this Story : Vancouver Sun Copy Link Email X Reddit LinkedIn Tumblr Su … download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Vancouver Sun ePaper, an electronic replica of t … download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articl … f the $250,000 he got from the 2009 Dr. Roger’s integrative medicine leadership prize to build the company. Like all small, privately-held biotech companies, Qu may eventually be bought by a giant pharmaceutical company. But that will largely depend on the safety of the product and the degree of benefit shown in clinical trials. Article content In the first randomized, controlled, clinical trial now accepting Crohn’s patients, one group will self-administer the drug while the
Podcast: The Natural Health Show Special Report on Crohn's December 7th & 8th, 2013 - QuIBD Current Trials No active IBD trials operating at this time Past Trials Crohn’s Disease Phase 2 – “part #1” Clinical Trial Experience in Crohn’s disease Clinical Trial Experience in Ulcerative Colitis Intro to SSIs How SSIs Work SSI Clinical History QBECO SSI Efficacy & Safety IBD Clinical Advisors Clinical Trial Doctors Resources Why Participate in a Clinical Trial Impact of IBD What is Crohn’s Disease? What is Ulcerative Colitis? Differences between Crohn’s D
Qu Biologics Enrolls First Two Participants In Phase 2a Clinical Trial For Lung Cancer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Qu Biologics Enrolls First Two Participants In Phase 2a Clinical Trial For Lung Cancer February 4, 2015 | 2 min read Twitter LinkedIn Facebook Email Print Vancouver, British Columbia - February 4, 2015 - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Qu IBD - Jini Patel Thompson, founder and director of... Facebook Вход Публикация Qu IBD Qu IBD 25 июль 2019 г. · Поделился/-ась с Доступно всем Jini Patel Thompson, founder and director of Listen To Your Gut, interviews Dr. Hal Gunn (CEO, Qu Biologics) & Dr. Shirin Kalyan (Director of Scientific Innovation, Qu Biologics) about Qu's treatment approach for #Crohns . blog.listentoyourgut.com Qu Biologics - New Podcast Available! | Listen To Your Gut Подробнее Все реакции: 21 Поделились: 9 Поставить "Нравится" Комментировать